Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFCI 95-096: RT +/- ADT in High Risk Prostate Cancer
NCT00116220Phase 3Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 1995
- Primary completion
- Apr 2001
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of flutamide, leuprolide and goserelin in prostate cancer (PCa) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Freedom from PSA failure at 2 years. Started Sep 1995; status: completed.
02
Drugs
flutamideleuprolidegoserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00116220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116220.